01 Expansion of Next-Generation Sequencing-Based Genetic Testing The genetic testing market is increasingly moving toward next-generation sequencing technologies capable of analyzing multiple genes and genetic variants within a single test. Broader sequencing panels can support evaluation of hereditary conditions, cancers, and other complex disorders without requiring separate tests for each genetic target. This is increasing the scope of genetic information available from a single clinical sample and supporting wider adoption of high-throughput genomic testing. In May 2026, the U.S. Food and Drug Administration approved a liquid-biopsy next-generation sequencing test capable of detecting genetic alterations across hundreds of genes from circulating cell-free DNA.
02 Growing Use of Genetic Testing for Treatment Selection Genetic testing is increasingly being incorporated into treatment pathways to identify biomarkers that can determine whether patients may benefit from specific therapies. Companion diagnostic testing is particularly expanding in oncology, where genetic alterations can be used to guide targeted treatment decisions. In March 2026, the U.S. Food and Drug Administration approved an updated companion-diagnostic indication for a genetic test to identify ovarian cancer patients with BRCA1 and BRCA2 mutations or genomic instability who may be eligible for a targeted therapy.
01 Rising Prevalence of Genetic and Hereditary Disorders Supports Testing Demand The identification and management of inherited disorders require genetic information that cannot always be obtained through conventional clinical assessment. Greater recognition of rare diseases and hereditary conditions is encouraging healthcare systems to use genetic testing to support diagnosis, carrier identification, and family risk assessment. Increasing clinical awareness of genetic contributions to disease is therefore expanding the population referred for testing.
01 Complex Interpretation of Genetic Results Limits Wider Utilization Genetic tests can identify variants whose clinical significance is uncertain or may change as scientific knowledge develops. Interpreting results often requires clinical context, family history, databases of genetic evidence, and specialist expertise. This complexity can make testing more difficult to integrate into routine care and can increase the need for genetic counseling and specialist review.
01 Expansion of Pharmacogenomic Testing Creates New Clinical Applications Pharmacogenomic testing can identify genetic variations that influence how individuals metabolize or respond to certain medicines. Greater incorporation of genetic information into prescribing decisions could create additional applications for testing across psychiatry, cardiology, oncology, and other therapeutic areas.
01 Unequal Access to Genetic Testing Infrastructure Access to genetic testing depends on the availability of specialized laboratories, sequencing technologies, trained professionals, genetic counseling, and reimbursement. These resources are unevenly distributed across healthcare systems and geographic regions, creating differences in patients' ability to obtain testing and appropriate interpretation. Infrastructure gaps can therefore limit the broader clinical adoption of advanced genetic testing.
June 2026 SOPHiA GENETICS signed a Memorandum of Understanding (MoU) with Memorial Sloan Kettering Cancer Center to establish a joint venture focused on developing next-generation precision oncology solutions by combining AI-powered genomic analytics with advanced clinical diagnostics.
June 2026 Roche launched the Axelios gene sequencing platform, introducing a new high-throughput sequencing system designed to expand its genomics portfolio and strengthen its position in the genetic testing and sequencing market.
June 2026 Natera entered a strategic partnership with Eledon Pharmaceuticals to integrate its Prospera™ donor-derived cell-free DNA genetic testing assay into Eledon's planned Phase III kidney transplant clinical trial.
March 2026 GeneDx partnered with Zevra Therapeutics to launch a sponsored genetic testing program that expands patient access to exome sequencing for suspected Niemann-Pick Disease Type C, supporting earlier diagnosis and precision care.